Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review
DOI:
https://doi.org/10.2340/actadv.v103.6525Keywords:
Calcineurin Inhibitors, Pimecrolimus, Psoriasis, Systematic Review, Tacrolimus, Treatment OutcomeAbstract
Facial and genital psoriasis impairs quality of life and is challenging to treat because of increased percutaneous penetration and, consequently, increased risk of adverse effects. Topical calcineurin inhibitors are recognized as a valid off-label treatment for these sensitive skin areas, but data on safety and efficacy are limited. This systematic review of the literature included 24 of 3,322 studies (5 randomized controlled trials, 9 open-label studies, 2 case series and 8 case reports). All studies demonstrated positive efficacy; 11 studies found statistically significant reductions in psoriasis severity. Local stinging, burning and itching were the most common short-term adverse effects and were reported in 18 studies. Topical calcineurin inhibitors appear to have an important role in the treatment of facial and genital psoriasis. The drugs are effective and generally well-tolerated with few adverse effects.
Downloads
References
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590.
https://doi.org/10.1136/bmj.m1590 DOI: https://doi.org/10.1136/bmj.m1590
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet (London, England) 2021; 397: 1301-1315.
https://doi.org/10.1016/S0140-6736(20)32549-6 DOI: https://doi.org/10.1016/S0140-6736(20)32549-6
Pincus SH. Vulvar dermatoses and pruritus vulvae. Dermatol Clin 1992; 10: 297-308.
https://doi.org/10.1016/S0733-8635(18)30336-X DOI: https://doi.org/10.1016/S0733-8635(18)30336-X
Shim TN, Ali I, Muneer A, Bunker CB. Benign male genital dermatoses. BMJ 2016; 354: i4337.
https://doi.org/10.1136/bmj.i4337 DOI: https://doi.org/10.1136/bmj.i4337
Meeuwis KAP, de Hullu JA, van de Nieuwenhof HP, Evers AWM, Massuger LFAG, van de Kerkhof PCM, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol 2011; 164: 1247-1255.
https://doi.org/10.1111/j.1365-2133.2011.10249.x DOI: https://doi.org/10.1111/j.1365-2133.2011.10249.x
Alpsoy E, Polat M, FettahlıoGlu-Karaman B, Karadag AS, Kartal-Durmazlar P, YalCın B, et al. Internalized stigma in psoriasis: a multicenter study. J Dermatol 2017; 44: 885-891.
https://doi.org/10.1111/1346-8138.13841 DOI: https://doi.org/10.1111/1346-8138.13841
Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 1967; 48: 181-183.
https://doi.org/10.1038/jid.1967.29 DOI: https://doi.org/10.1038/jid.1967.29
Britz MB, Maibach HI, Anjo DM. Human percutaneous penetration of hydrocortisone: the vulva. Arch Dermatol Res 1980; 267: 313-316.
https://doi.org/10.1007/BF00403852 DOI: https://doi.org/10.1007/BF00403852
Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane database Syst Rev 2013: CD005028.
https://doi.org/10.1002/14651858.CD005028.pub3 DOI: https://doi.org/10.1002/14651858.CD005028.pub3
Lebwohl MG, Tan MH, Meador SL, Singer G. Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001; 44: 77-82.
https://doi.org/10.1067/mjd.2001.110046 DOI: https://doi.org/10.1067/mjd.2001.110046
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-8.
https://doi.org/10.1016/j.jaad.2005.01.010 DOI: https://doi.org/10.1016/j.jaad.2005.01.010
Kienbaum S, Lehmann P, Ruzicka T. Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol 1996; 135: 647-650. DOI: https://doi.org/10.1111/j.1365-2133.1996.tb03851.x
https://doi.org/10.1046/j.1365-2133.1996.d01-1060.x DOI: https://doi.org/10.1046/j.1365-2133.1996.d01-1060.x
Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol 1992; 27: 1001-1008.
https://doi.org/10.1016/0190-9622(92)70302-V DOI: https://doi.org/10.1016/0190-9622(92)70302-V
Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004; 151: 3-27.
https://doi.org/10.1111/j.1365-2133.2004.06269.x DOI: https://doi.org/10.1111/j.1365-2133.2004.06269.x
Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-398.
https://doi.org/10.1046/j.1523-1747.1998.00323.x DOI: https://doi.org/10.1046/j.1523-1747.1998.00323.x
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
https://doi.org/10.1136/bmj.b2535 DOI: https://doi.org/10.1136/bmj.b2535
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016; 5: 210.
https://doi.org/10.1186/s13643-016-0384-4 DOI: https://doi.org/10.1186/s13643-016-0384-4
Wells G, Shea B, O'Connell D, Peterson J. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ottawa Hosp Res Inst 2000 [cited 2022 Jun 1]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Yamamoto T, Nishioka K. Deep dermatophytosis during topical tacrolimus therapy for psoriasis. Acta Derm Venereol 2003; 83: 291-292.
https://doi.org/10.1080/00015550310016571 DOI: https://doi.org/10.1080/00015550310016571
Canpolat F, Cemil BC, Tatlican S, Eskioglu F, Oktay M, Alper M. Pimecrolimus 1% cream is effective in the treatment of psoriasis in an infant. Eur J Dermatol 2009; 19: 168-169.
https://doi.org/10.1684/ejd.2008.0583 DOI: https://doi.org/10.1684/ejd.2008.0583
Yao XJ, Zhang TD. Psoriasis localized to the glans penis in a 37-year-old man. CMAJ 2018; 190: E747.
https://doi.org/10.1503/cmaj.180262 DOI: https://doi.org/10.1503/cmaj.180262
Yamamoto T, Nishioka K. Successful treatment with topical tacrolimus for oral psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1137-1138.
https://doi.org/10.1111/j.1468-3083.2006.01630.x DOI: https://doi.org/10.1111/j.1468-3083.2006.01630.x
Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 2003; 13: 471-473.
Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 2000; 80: 451.
Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007; 157: 1005-1012.
https://doi.org/10.1111/j.1365-2133.2007.08201.x DOI: https://doi.org/10.1111/j.1365-2133.2007.08201.x
Kreuter A, Sommer A, Hyun J, Bräutigam M, Brockmeyer NH, Altmeyer P, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006; 142: 1138-1143.
https://doi.org/10.1001/archderm.142.9.1138 DOI: https://doi.org/10.1001/archderm.142.9.1138
Jacobi A, Braeutigam M, Mahler V, Schultz E, Hertl M. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology 2008; 216: 133-136.
https://doi.org/10.1159/000111510 DOI: https://doi.org/10.1159/000111510
Rallis E, Nasiopoulou A, Kouskoukis C, Roussaki-Schulze A, Koumantaki E, Karpouzis A, et al. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res 2005; 31: 141-145.
Karajovanov ID, Najdova A, Nikolovska S, Damevska K, Duma S. Psoriasis inversa in child-case report. J Dermatol Nurses Assoc 2020; 12.
Kleyn CE, Woodcock D, Sharpe GR. The efficacy of 0.1% tacrolimus ointment compared with clobetasone butyrate 0.05% ointment in patients with facial, flexural or genital psoriasis. Br J Dermatol 2005; 153: 33.
Frigerio E, Taglioni M, Franchi C, Garutti C, Spadino S, Altomare A, et al. The use of pimecrolimus cream 1% in the treatment of facial psoriasis. G Ital di Dermatologia e Venereol 2006; 141: 415-419.
Clayton T, Harrison PV, Nicholls R, Delap M. Topical tacrolimus for facial psoriasis. Br J Dermatol 2003; 149: 419-420.
https://doi.org/10.1046/j.1365-2133.2003.05426.x DOI: https://doi.org/10.1046/j.1365-2133.2003.05426.x
Martín Ezquerra G, Sánchez Regaña M, Herrera Acosta E, Umbert Millet P. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 2006; 5: 334-336.
Kroft EB, Erceg A, Maimets K, Vissers W, van der Valk PGM, van de Kerkhof PCM. Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol 2005; 19: 249-251.
https://doi.org/10.1111/j.1468-3083.2005.01122.x DOI: https://doi.org/10.1111/j.1468-3083.2005.01122.x
Mansouri P, Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J 2006; 12: 7.
https://doi.org/10.5070/D37C3542MX DOI: https://doi.org/10.5070/D37C3542MX
Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol 2004; 18: 742-743.
https://doi.org/10.1111/j.1468-3083.2004.01054.x DOI: https://doi.org/10.1111/j.1468-3083.2004.01054.x
Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J Cutan Med Surg 2008; 12: 230-234.
https://doi.org/10.2310/7750.2008.07055 DOI: https://doi.org/10.2310/7750.2008.07055
Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731-738.
https://doi.org/10.1016/j.jaad.2004.06.010 DOI: https://doi.org/10.1016/j.jaad.2004.06.010
Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48: 564-568.
https://doi.org/10.1067/mjd.2003.169 DOI: https://doi.org/10.1067/mjd.2003.169
Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-730.
https://doi.org/10.1016/j.jaad.2004.07.011 DOI: https://doi.org/10.1016/j.jaad.2004.07.011
Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007; 24: 76-80.
https://doi.org/10.1111/j.1525-1470.2007.00341.x DOI: https://doi.org/10.1111/j.1525-1470.2007.00341.x
Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 2005; 53: 713-716.
https://doi.org/10.1016/j.jaad.2005.05.036 DOI: https://doi.org/10.1016/j.jaad.2005.05.036
Oriba HA, Bucks DA, Maibach HI. Percutaneous absorption of hydrocortisone and testosterone on the vulva and forearm: effect of the menopause and site. Br J Dermatol 1996; 134: 229-233. DOI: https://doi.org/10.1046/j.1365-2133.1996.d01-787.x
https://doi.org/10.1111/j.1365-2133.1996.tb07606.x DOI: https://doi.org/10.1111/j.1365-2133.1996.tb07606.x
Young Park J, Hyun Rim J, Beom Choe Y, Il Youn J. Facial psoriasis: comparison of patients with and without facial involvement. J Am Acad Dermatol 2004; 50: 582-584.
https://doi.org/10.1016/S0190-9622(03)02793-2 DOI: https://doi.org/10.1016/S0190-9622(03)02793-2
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020; 82: 117-122.
https://doi.org/10.1016/j.jaad.2019.08.026 DOI: https://doi.org/10.1016/j.jaad.2019.08.026
Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004; 151: 895-897.
https://doi.org/10.1111/j.1365-2133.2004.06174.x DOI: https://doi.org/10.1111/j.1365-2133.2004.06174.x
Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269: 29-35.
https://doi.org/10.1016/j.ijpharm.2003.07.013 DOI: https://doi.org/10.1016/j.ijpharm.2003.07.013
Paller AS, Lebwohl M, Fleischer ABJ, Antaya R, Langley RG, Kirsner RS, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 810-822.
https://doi.org/10.1016/j.jaad.2004.12.038 DOI: https://doi.org/10.1016/j.jaad.2004.12.038
Van Leent EJM, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002; 204: 63-68.
https://doi.org/10.1159/000051813 DOI: https://doi.org/10.1159/000051813
Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr 2016; 16: 75.
https://doi.org/10.1186/s12887-016-0607-9 DOI: https://doi.org/10.1186/s12887-016-0607-9
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar MLA, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015; 135: 597-606.
https://doi.org/10.1542/peds.2014-1990 DOI: https://doi.org/10.1542/peds.2014-1990
Soter NA, Fleischer AB, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety. J Am Acad Dermatol 2001; 44: S39-S46.
https://doi.org/10.1067/mjd.2001.109817 DOI: https://doi.org/10.1067/mjd.2001.109817
Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28-S38.
https://doi.org/10.1067/mjd.2001.109810 DOI: https://doi.org/10.1067/mjd.2001.109810
Halling-Overgaard AS, Kezic S, Jakasa I, Engebretsen KA, Maibach H, Thyssen JP. Skin absorption through atopic dermatitis skin: a systematic review. Br J Dermatol 2017; 177: 84-106.
https://doi.org/10.1111/bjd.15065 DOI: https://doi.org/10.1111/bjd.15065
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Diva Amiri, Christopher Willy Schwarz, Lise Gether, Lone Skov
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
